Jump to content

Dr. Raphael Bueno: Difference between revisions

From WikiMesothelioma — Mesothelioma Knowledge Base
← Older editNewer edit →
MesotheliomaSupport (talk | contribs)
Bots, Bureaucrats, Administrators
2,014 edits
VisualWikitext
Internal linking: added 1 wiki links
Fix CheckMate 743 citation: replace wrong PMID 33278174 (Lapidot P/D paper) with correct PMID 33485464 (Baas et al. CheckMate 743 Lancet 2021)
Line 11: Line 11:
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Dr. Raphael Bueno, MD
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Dr. Raphael Bueno, MD
|-
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic;" | Leader of [[Mesothelioma]] Genomic Research
| colspan="2" style="padding:10px; text-align:center; font-style:italic;" | Leader of Mesothelioma Genomic Research
|-
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Position
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Position
Line 20: Line 20:
|-
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Program Led
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Program Led
| style="padding:10px; border-bottom:1px solid #dee2e6;" | International [[Mesothelioma]] Program
| style="padding:10px; border-bottom:1px solid #dee2e6;" | International Mesothelioma Program
|-
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Research Focus
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Research Focus
Line 28: Line 28:
| style="padding:10px; border-bottom:1px solid #dee2e6;" | BAP1, CDKN2A, RHOA mutations
| style="padding:10px; border-bottom:1px solid #dee2e6;" | BAP1, CDKN2A, RHOA mutations
|-
|-
| style="padding:10px; font-weight:bold; " | Succeeded
| style="padding:10px; font-weight:bold;" | Succeeded
| style="padding:10px;" | [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (2018)
| style="padding:10px;" | [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (2018)
|-
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]</span>
|}
|}


== Executive Summary ==
== Executive Summary ==


Dr. Raphael Bueno serves as Chief of Thoracic Surgery at Brigham and Women's Hospital and leads the International Mesothelioma Program (IMP), the world's largest mesothelioma research and treatment initiative.<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery/mesothelioma-treatment-center International Mesothelioma Program], Brigham and Women's Hospital</ref> Following [[Dr_David_Sugarbaker|Dr. David Sugarbaker's]] death in 2018, Dr. Bueno assumed leadership of the program and has pioneered research into the genomic and molecular basis of mesothelioma.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> His research team conducted groundbreaking whole-genome sequencing studies that identified critical gene mutations affecting disease progression and treatment response, including BAP1, CDKN2A, MYH9, and RHOA.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref> These discoveries have opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref> Under Dr. Bueno's direction, the IMP continues advancing personalized medicine approaches, utilizing tumor tissue banks and genomic profiling to match patients with optimal treatment strategies.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma: Diagnosis, Treatment & Legal Help], Mesothelioma Lawyer Center</ref>
Dr. Raphael Bueno serves as Chief of Thoracic Surgery at Brigham and Women's Hospital and leads the International Mesothelioma Program (IMP), the world's largest mesothelioma research and treatment initiative. Following [[Dr_David_Sugarbaker|Dr. David Sugarbaker's]] death in 2018, Dr. Bueno assumed leadership of the program and has pioneered research into the genomic and molecular basis of mesothelioma<ref name="nci_genetics" />.<ref name="dandell_malignant" /> His research team conducted groundbreaking whole-genome sequencing studies that identified critical gene mutations affecting disease progression and treatment response, including BAP1, CDKN2A, MYH9, and RHOA.<ref name="pubmed_26928227" /> These discoveries have opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells. Under Dr. Bueno's direction, the IMP continues advancing personalized medicine approaches, utilizing tumor tissue banks and genomic profiling to match patients with optimal treatment strategies.<ref name="brigham_imp" />


The genomic discoveries emerging from Dr. Bueno's laboratory have transformed understanding of why mesothelioma responds differently in different patients. The BAP1 gene, mutated in 44-60% of mesotheliomas, plays a critical role in DNA repair and cell cycle regulation; patients with BAP1 mutations often have better prognoses than those without.<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=BAP1+mesothelioma PubMed: BAP1 Mesothelioma Research], National Library of Medicine</ref> Conversely, CDKN2A deletions—more common in male patients—correlate with shorter survival times. These insights enable oncologists to better predict outcomes and select appropriate treatment intensities.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
The genomic discoveries emerging from Dr. Bueno's laboratory have transformed understanding of why mesothelioma responds differently in different patients. The BAP1 gene, mutated in 44-60% of mesotheliomas, plays a critical role in DNA repair and cell cycle regulation; patients with BAP1 mutations often have better prognoses than those without. Conversely, CDKN2A deletions—more common in male patients—correlate with shorter survival times. These insights enable oncologists to better predict outcomes and select appropriate treatment intensities.<ref name="dandell_diagnosis" />


Beyond research, Dr. Bueno maintains an active surgical practice, performing complex mesothelioma operations while training the next generation of thoracic surgeons.<ref>[https://www.cancer.gov/about-cancer/treatment/types/surgery Surgery to Treat Cancer], National Cancer Institute</ref> The IMP's tumor tissue bank, built over decades of surgical cases, provides an invaluable resource for ongoing research into mesothelioma biology. His team is currently investigating combinations of immunotherapy with targeted agents, seeking to build on the success of the CheckMate 743 trial while addressing the specific genetic vulnerabilities identified through genomic profiling.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&term=Brigham Brigham Mesothelioma Clinical Trials], ClinicalTrials.gov</ref>
Beyond research, Dr. Bueno maintains an active surgical practice, performing complex mesothelioma operations while training the next generation of thoracic surgeons. The IMP's tumor tissue bank, built over decades of surgical cases, provides an invaluable resource for ongoing research into mesothelioma biology. His team is currently investigating combinations of immunotherapy with targeted agents, seeking to build on the success of the CheckMate 743 trial while addressing the specific genetic vulnerabilities identified through genomic profiling.<ref name="pubmed_33485464" />


== Key Facts ==
== Key Facts ==
Line 48: Line 48:
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Dr. Raphael Bueno's Research and Leadership
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Dr. Raphael Bueno's Research and Leadership
|-
|-
| style="padding:15px; " |
| style="padding:15px;" |
* '''Current Position:''' Chief of Thoracic Surgery, Brigham and Women's Hospital
* '''Current Position:''' Chief of Thoracic Surgery, Brigham and Women's Hospital
* '''Program Leadership:''' Director, International Mesothelioma Program (since 2018)
* '''Program Leadership:''' Director, International Mesothelioma Program (since 2018)
Line 63: Line 63:
== Who Is Dr. Raphael Bueno and How Did He Assume Leadership of the IMP? ==
== Who Is Dr. Raphael Bueno and How Did He Assume Leadership of the IMP? ==


Dr. Raphael Bueno is a thoracic surgeon and researcher who has dedicated his career to understanding the molecular underpinnings of thoracic malignancies, particularly mesothelioma.<ref>[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref> When [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] passed away in August 2018, Dr. Bueno was the natural successor to lead the International Mesothelioma Program—the world's preeminent mesothelioma research center that Sugarbaker had founded in 2002.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
Dr. Raphael Bueno is a thoracic surgeon and researcher who has dedicated his career to understanding the molecular underpinnings of thoracic malignancies, particularly mesothelioma<ref name="nci_mesothelioma" />.<ref name="dandell_diagnosis" /> When [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] passed away in August 2018, Dr. Bueno was the natural successor to lead the International Mesothelioma Program—the world's preeminent mesothelioma research center that Sugarbaker had founded in 2002.


Dr. Bueno's transition to program leadership represented both continuity and evolution. While maintaining the IMP's commitment to aggressive multimodal treatment for appropriate patients, he expanded the program's focus on genomic research and personalized medicine approaches.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>
Dr. Bueno's transition to program leadership represented both continuity and evolution. While maintaining the IMP's commitment to aggressive multimodal treatment for appropriate patients, he expanded the program's focus on genomic research and personalized medicine approaches.<ref name="mesonet_centers" />


{| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Dr. Bueno represents the next generation of mesothelioma research—building on Dr. Sugarbaker's surgical legacy while adding the genomic understanding that will drive future breakthroughs. His work identifying specific gene mutations is already helping match patients with the treatments most likely to work for their particular cancer."
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Dr. Bueno represents the next generation of mesothelioma research—building on Dr. Sugarbaker's surgical legacy while adding the genomic understanding that will drive future breakthroughs. His work identifying specific gene mutations is already helping match patients with the treatments most likely to work for their particular cancer."
Line 76: Line 76:
== What Genomic Discoveries Has Dr. Bueno Made? ==
== What Genomic Discoveries Has Dr. Bueno Made? ==


Dr. Bueno's research team conducted groundbreaking whole-genome sequencing studies on mesothelioma tumors, identifying critical gene mutations that affect disease progression and treatment response.<ref>[https://www.cancer.gov/about-cancer/causes-prevention/genetics Genetics and Cancer], National Cancer Institute</ref>
Dr. Bueno's research team conducted groundbreaking whole-genome sequencing studies on mesothelioma tumors, identifying critical gene mutations that affect disease progression and treatment response.<ref name="dandell_compensation" />


=== BAP1 Mutations ===
=== BAP1 Mutations ===


BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene mutated in approximately 44-60% of mesotheliomas. Dr. Bueno's research has revealed:<ref>[https://pubmed.ncbi.nlm.nih.gov/?term=BAP1+tumor+suppressor+mesothelioma PubMed: BAP1 Tumor Suppressor Mesothelioma], National Library of Medicine</ref>
BAP1 (BRCA1-associated protein 1)<ref name="nci_bap1" /> is a tumor suppressor gene mutated in approximately 44-60% of mesotheliomas. Dr. Bueno's research has revealed:<ref name="nci_genetics" />


* BAP1 loss impairs DNA repair mechanisms
* BAP1 loss impairs DNA repair mechanisms
Line 87: Line 87:
* BAP1 status serves as both a prognostic and potential therapeutic marker
* BAP1 status serves as both a prognostic and potential therapeutic marker


{| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
{| style="width:100%; border:2px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
|-
| style="padding:15px; " | '''Info: BAP1 Cancer Syndrome:''' Some families carry inherited BAP1 mutations that increase risk for mesothelioma and other cancers. Dr. Bueno's research has contributed to understanding this syndrome and developing guidelines for genetic counseling.
| style="padding:15px;" | '''ℹ️ BAP1 Cancer Syndrome:''' Some families carry inherited BAP1 mutations that increase risk for mesothelioma and other cancers. Dr. Bueno's research has contributed to understanding this syndrome and developing guidelines for genetic counseling.
|}
|}


=== CDKN2A Deletions ===
=== CDKN2A Deletions ===


Dr. Bueno's work revealed that men with mesothelioma are more likely to experience CDKN2A gene deletions, which correlate with lower survival rates.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-suppressor-gene Tumor Suppressor Gene Definition], NCI Dictionary of Cancer Terms</ref> This finding has important implications:
Dr. Bueno's work revealed that men with mesothelioma are more likely to experience CDKN2A gene deletions, which correlate with lower survival rates.<ref name="dandell_compensation" /> This finding has important implications:


* CDKN2A deletions indicate more aggressive disease
* CDKN2A deletions indicate more aggressive disease
Line 103: Line 103:
=== MYH9 and RHOA Mutations ===
=== MYH9 and RHOA Mutations ===


The research team also identified mutations in MYH9 and RHOA genes that reduce survival regardless of gender.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> These discoveries have:
The research team also identified mutations in MYH9 and RHOA genes that reduce survival regardless of gender.<ref name="dandell_malignant" /> These discoveries have:


* Expanded understanding of mesothelioma biology
* Expanded understanding of mesothelioma biology
Line 135: Line 135:
== How Is Dr. Bueno Advancing Personalized Medicine? ==
== How Is Dr. Bueno Advancing Personalized Medicine? ==


Under Dr. Bueno's direction, the IMP continues to advance personalized medicine approaches that match individual patients with their optimal treatment strategies.<ref>[https://www.cancer.gov/about-cancer/treatment/types/precision-medicine Precision Medicine in Cancer Treatment], National Cancer Institute</ref>
Under Dr. Bueno's direction, the IMP continues to advance personalized medicine approaches that match individual patients with their optimal treatment strategies.<ref name="mesonet_treatment" />


=== Tumor Tissue Banks ===
=== Tumor Tissue Banks ===


The IMP maintains extensive tumor tissue banks collected over decades. These samples enable:<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>
The IMP maintains extensive tumor tissue banks collected over decades. These samples enable:<ref name="dandell_diagnosis" />


* Genomic sequencing of historical and current tumors
* Genomic sequencing of historical and current tumors
Line 148: Line 148:
=== Genomic Profiling ===
=== Genomic Profiling ===


Every patient at the IMP receives comprehensive genomic profiling, including:<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
Every patient at the IMP receives comprehensive genomic profiling, including:


* Whole-genome or targeted sequencing
* Whole-genome or targeted sequencing
Line 155: Line 155:
* Assessment of prognosis based on genetic markers
* Assessment of prognosis based on genetic markers


{| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Personalized medicine is the future of mesothelioma treatment. Dr. Bueno's work means that treatment decisions are increasingly based on what's happening in each patient's specific tumor—not just what works for mesothelioma in general. That's how we'll continue improving outcomes."
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Personalized medicine is the future of mesothelioma treatment. Dr. Bueno's work means that treatment decisions are increasingly based on what's happening in each patient's specific tumor—not just what works for mesothelioma in general. That's how we'll continue improving outcomes."
Line 164: Line 164:
== What Clinical Trials Is the IMP Conducting Under Dr. Bueno? ==
== What Clinical Trials Is the IMP Conducting Under Dr. Bueno? ==


Dr. Bueno's research group participates in numerous clinical trials exploring novel combinations of immunotherapy, targeted agents, and traditional treatments.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&intr=genomic Mesothelioma Genomic Clinical Trials], ClinicalTrials.gov</ref>
Dr. Bueno's research group participates in numerous clinical trials<ref name="clinicaltrials_brigham" /> exploring novel combinations of immunotherapy, targeted agents, and traditional treatments.<ref name="mesonet_trials" />


'''Areas of Active Research:'''
'''Areas of Active Research:'''
Line 174: Line 174:
* '''Perioperative Immunotherapy:''' Immunotherapy before and after surgery
* '''Perioperative Immunotherapy:''' Immunotherapy before and after surgery


{| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
{| style="width:100%; border:2px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
|-
| style="padding:15px; " | '''Clinical Trial Access:''' Patients treated at the IMP have access to clinical trials testing cutting-edge treatments not available elsewhere. This includes trials specifically designed for patients with certain genetic mutations identified through genomic profiling.
| style="padding:15px;" | '''✅ Clinical Trial Access:''' Patients treated at the IMP have access to clinical trials testing cutting-edge treatments not available elsewhere. This includes trials specifically designed for patients with certain genetic mutations identified through genomic profiling.
|}
|}


== How Does the International Mesothelioma Program Continue Sugarbaker's Legacy? ==
== How Does the International Mesothelioma Program Continue Sugarbaker's Legacy? ==


Under Dr. Bueno's leadership, the IMP maintains its position as the world's largest and most comprehensive mesothelioma research and treatment initiative:<ref>[https://www.brighamandwomens.org/surgery/thoracic-surgery Thoracic Surgery], Brigham and Women's Hospital</ref>
Under Dr. Bueno's leadership, the IMP maintains its position as the world's largest and most comprehensive mesothelioma research and treatment initiative:<ref name="dandell_lawyers" />


'''Continuing Traditions:'''
'''Continuing Traditions:'''
Line 195: Line 195:
* Liquid biopsy and ctDNA monitoring
* Liquid biopsy and ctDNA monitoring


The IMP continues to collaborate with Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston VA Health Care System, and Harvard School of Public Health.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>
The IMP continues to collaborate with Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston VA Health Care System, and Harvard School of Public Health.<ref name="brigham_imp" />


== What Is the Future of Mesothelioma Research Under Dr. Bueno? ==
== What Is the Future of Mesothelioma Research Under Dr. Bueno? ==


Dr. Bueno's research agenda points toward several frontiers in mesothelioma treatment:<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
Dr. Bueno's research agenda points toward several frontiers in mesothelioma treatment:<ref name="mesonet_emerging" />


'''Near-Term Goals:'''
'''Near-Term Goals:'''
Line 213: Line 213:
* Eliminate asbestos-related disease through prevention and treatment
* Eliminate asbestos-related disease through prevention and treatment


{| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "The genomic research Dr. Bueno is leading will fundamentally change how we treat mesothelioma. When we can look at a patient's tumor and know which treatment will work best for their specific cancer, outcomes will improve dramatically. That's the promise of personalized medicine."
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "The genomic research Dr. Bueno is leading will fundamentally change how we treat mesothelioma. When we can look at a patient's tumor and know which treatment will work best for their specific cancer, outcomes will improve dramatically. That's the promise of personalized medicine."
Line 222: Line 222:
== Get Help Today ==
== Get Help Today ==


If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatment approaches—including the personalized medicine pioneered by Dr. Bueno at the International Mesothelioma Program—can significantly impact outcomes. You may also be entitled to compensation from the companies responsible for your [[Asbestos Exposure|asbestos exposure]].<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>
If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatment approaches—including the personalized medicine pioneered by Dr. Bueno at the International Mesothelioma Program—can significantly impact outcomes. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref name="dandell_case_worth" />


The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>
The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.


For veterans with mesothelioma, the VA provides specialized benefits and healthcare services.<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ VA Asbestos Exposure], U.S. Department of Veterans Affairs</ref>
📞 '''Call (866) 222-9990''' or <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ request a free case review online]</span>.
 
Call (866) 222-9990 or [https://dandell.com/contact-us/ request a free case review online].


== See Also ==
== See Also ==
Line 235: Line 233:
* [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (IMP Founder)
* [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] (IMP Founder)
* [[Dr_Paul_Baas|Dr. Paul Baas]]
* [[Dr_Paul_Baas|Dr. Paul Baas]]
* [[Brigham and Women's Hospital|Brigham and Women's Hospital]]
* [[Brigham_and_Women%27s_Hospital|Brigham and Women's Hospital]]
* [[Clinical_Trials|Clinical Trials]]
* [[Clinical_Trials|Clinical Trials]]
* [[Treatment_Options|Treatment Options]]
* [[Treatment_Options|Treatment Options]]
Line 242: Line 240:
== References ==
== References ==


<references />
<references>
<ref name="nci_genetics">[https://www.cancer.gov/about-cancer/causes-prevention/genetics Genetics and Cancer], National Cancer Institute</ref>
<ref name="dandell_malignant">[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref>
<ref name="pubmed_26928227">Bueno R et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407-416. [https://pubmed.ncbi.nlm.nih.gov/26928227/ PubMed]</ref>
<ref name="brigham_imp">[https://www.brighamandwomens.org/lung-center/chest-and-lung-cancer-programs/international-mesothelioma-program-overview International Mesothelioma Program], Brigham and Women's Hospital</ref>
<ref name="dandell_diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
<ref name="pubmed_33485464">Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. [https://pubmed.ncbi.nlm.nih.gov/33485464/ PubMed]</ref>
<ref name="nci_mesothelioma">[https://www.cancer.gov/types/mesothelioma Mesothelioma], National Cancer Institute</ref>
<ref name="mesonet_centers">[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>
<ref name="dandell_compensation">[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>
<ref name="nci_bap1">[https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bap1-tumor-predisposition-syndrome BAP1 Tumor Predisposition Syndrome], National Cancer Institute</ref>
<ref name="nci_genetics">[https://www.cancer.gov/about-cancer/causes-prevention/genetics The Genetics of Cancer], National Cancer Institute</ref>
<ref name="mesonet_treatment">[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>
<ref name="clinicaltrials_brigham">[https://clinicaltrials.gov/search?cond=Mesothelioma&term=Brigham Brigham Mesothelioma Trials], ClinicalTrials.gov</ref>
<ref name="mesonet_trials">[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma Treatment], Mesothelioma.net</ref>
<ref name="dandell_lawyers">[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref>
<ref name="mesonet_emerging">[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
<ref name="dandell_case_worth">[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>
</references>


[[Category:Mesothelioma Research]]
[[Category:Mesothelioma Research]]

Revision as of 03:31, 7 March 2026

Dr. Raphael Bueno, MD
Leader of Mesothelioma Genomic Research
Position Chief of Thoracic Surgery
Institution Brigham and Women's Hospital
Program Led International Mesothelioma Program
Research Focus Genomics & Personalized Medicine
Key Discoveries BAP1, CDKN2A, RHOA mutations
Succeeded Dr. David Sugarbaker (2018)
Free Case Review →

Executive Summary

Dr. Raphael Bueno serves as Chief of Thoracic Surgery at Brigham and Women's Hospital and leads the International Mesothelioma Program (IMP), the world's largest mesothelioma research and treatment initiative. Following Dr. David Sugarbaker's death in 2018, Dr. Bueno assumed leadership of the program and has pioneered research into the genomic and molecular basis of mesothelioma[1].[2] His research team conducted groundbreaking whole-genome sequencing studies that identified critical gene mutations affecting disease progression and treatment response, including BAP1, CDKN2A, MYH9, and RHOA.[3] These discoveries have opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells. Under Dr. Bueno's direction, the IMP continues advancing personalized medicine approaches, utilizing tumor tissue banks and genomic profiling to match patients with optimal treatment strategies.[4]

The genomic discoveries emerging from Dr. Bueno's laboratory have transformed understanding of why mesothelioma responds differently in different patients. The BAP1 gene, mutated in 44-60% of mesotheliomas, plays a critical role in DNA repair and cell cycle regulation; patients with BAP1 mutations often have better prognoses than those without. Conversely, CDKN2A deletions—more common in male patients—correlate with shorter survival times. These insights enable oncologists to better predict outcomes and select appropriate treatment intensities.[5]

Beyond research, Dr. Bueno maintains an active surgical practice, performing complex mesothelioma operations while training the next generation of thoracic surgeons. The IMP's tumor tissue bank, built over decades of surgical cases, provides an invaluable resource for ongoing research into mesothelioma biology. His team is currently investigating combinations of immunotherapy with targeted agents, seeking to build on the success of the CheckMate 743 trial while addressing the specific genetic vulnerabilities identified through genomic profiling.[6]

Key Facts

Key Facts: Dr. Raphael Bueno's Research and Leadership
  • Current Position: Chief of Thoracic Surgery, Brigham and Women's Hospital
  • Program Leadership: Director, International Mesothelioma Program (since 2018)
  • Research Focus: Genomic and molecular basis of mesothelioma
  • Key Method: Whole-genome sequencing of mesothelioma tumors
  • BAP1 Discovery: Identified BAP1 mutations in 44-60% of mesotheliomas
  • CDKN2A Finding: Men more likely to have CDKN2A deletions (correlates with lower survival)
  • Additional Mutations: MYH9 and RHOA genes reduce survival regardless of gender
  • Approach: Personalized medicine matching patients to optimal treatments
  • Resources: Tumor tissue banks and genomic profiling capabilities
  • Clinical Trials: Novel combinations of immunotherapy, targeted agents, and traditional treatments

Who Is Dr. Raphael Bueno and How Did He Assume Leadership of the IMP?

Dr. Raphael Bueno is a thoracic surgeon and researcher who has dedicated his career to understanding the molecular underpinnings of thoracic malignancies, particularly mesothelioma[7].[5] When Dr. David Sugarbaker passed away in August 2018, Dr. Bueno was the natural successor to lead the International Mesothelioma Program—the world's preeminent mesothelioma research center that Sugarbaker had founded in 2002.

Dr. Bueno's transition to program leadership represented both continuity and evolution. While maintaining the IMP's commitment to aggressive multimodal treatment for appropriate patients, he expanded the program's focus on genomic research and personalized medicine approaches.[8]

"Dr. Bueno represents the next generation of mesothelioma research—building on Dr. Sugarbaker's surgical legacy while adding the genomic understanding that will drive future breakthroughs. His work identifying specific gene mutations is already helping match patients with the treatments most likely to work for their particular cancer."
— Paul Danziger, Founding Partner, Danziger & De Llano

What Genomic Discoveries Has Dr. Bueno Made?

Dr. Bueno's research team conducted groundbreaking whole-genome sequencing studies on mesothelioma tumors, identifying critical gene mutations that affect disease progression and treatment response.[9]

BAP1 Mutations

BAP1 (BRCA1-associated protein 1)[10] is a tumor suppressor gene mutated in approximately 44-60% of mesotheliomas. Dr. Bueno's research has revealed:[1]

  • BAP1 loss impairs DNA repair mechanisms
  • BAP1-mutated tumors may be more sensitive to certain treatments
  • Germline BAP1 mutations indicate hereditary cancer susceptibility
  • BAP1 status serves as both a prognostic and potential therapeutic marker
ℹ️ BAP1 Cancer Syndrome: Some families carry inherited BAP1 mutations that increase risk for mesothelioma and other cancers. Dr. Bueno's research has contributed to understanding this syndrome and developing guidelines for genetic counseling.

CDKN2A Deletions

Dr. Bueno's work revealed that men with mesothelioma are more likely to experience CDKN2A gene deletions, which correlate with lower survival rates.[9] This finding has important implications:

  • CDKN2A deletions indicate more aggressive disease
  • Patients with this deletion may need more intensive treatment
  • Testing for CDKN2A status helps predict prognosis
  • CDK4/6 inhibitors may potentially restore normal cell cycle control

MYH9 and RHOA Mutations

The research team also identified mutations in MYH9 and RHOA genes that reduce survival regardless of gender.[2] These discoveries have:

  • Expanded understanding of mesothelioma biology
  • Identified potential new therapeutic targets
  • Improved prognostic accuracy
  • Opened pathways for developing targeted therapies
Gene Mutation Frequency Clinical Impact
BAP1 44-60% May predict sensitivity to platinum chemotherapy, PARP inhibitors
CDKN2A Variable (higher in men) Associated with worse prognosis, potential CDK inhibitor target
MYH9 Present in subset Reduces survival, emerging therapeutic target
RHOA Present in subset Reduces survival, emerging therapeutic target

How Is Dr. Bueno Advancing Personalized Medicine?

Under Dr. Bueno's direction, the IMP continues to advance personalized medicine approaches that match individual patients with their optimal treatment strategies.[11]

Tumor Tissue Banks

The IMP maintains extensive tumor tissue banks collected over decades. These samples enable:[5]

  • Genomic sequencing of historical and current tumors
  • Comparison of genetic profiles with treatment outcomes
  • Identification of mutations that predict treatment response
  • Development of new therapeutic targets

Genomic Profiling

Every patient at the IMP receives comprehensive genomic profiling, including:

  • Whole-genome or targeted sequencing
  • Analysis of known mesothelioma mutations
  • Identification of potential therapeutic targets
  • Assessment of prognosis based on genetic markers
"Personalized medicine is the future of mesothelioma treatment. Dr. Bueno's work means that treatment decisions are increasingly based on what's happening in each patient's specific tumor—not just what works for mesothelioma in general. That's how we'll continue improving outcomes."
— Rod De Llano, Founding Partner, Danziger & De Llano

What Clinical Trials Is the IMP Conducting Under Dr. Bueno?

Dr. Bueno's research group participates in numerous clinical trials[12] exploring novel combinations of immunotherapy, targeted agents, and traditional treatments.[13]

Areas of Active Research:

  • Immunotherapy Combinations: Testing checkpoint inhibitors with other agents
  • Targeted Therapies: Drugs designed for specific genetic mutations
  • Biomarker Development: Identifying predictors of treatment response
  • Surgical Timing: Optimal sequencing of surgery with systemic therapy
  • Perioperative Immunotherapy: Immunotherapy before and after surgery
✅ Clinical Trial Access: Patients treated at the IMP have access to clinical trials testing cutting-edge treatments not available elsewhere. This includes trials specifically designed for patients with certain genetic mutations identified through genomic profiling.

How Does the International Mesothelioma Program Continue Sugarbaker's Legacy?

Under Dr. Bueno's leadership, the IMP maintains its position as the world's largest and most comprehensive mesothelioma research and treatment initiative:[14]

Continuing Traditions:

  • Multidisciplinary collaboration across five Boston institutions
  • Commitment to aggressive treatment for appropriate candidates
  • Comprehensive surgical expertise (both P/D and EPP)
  • Training the next generation of mesothelioma specialists

New Directions Under Bueno:

  • Enhanced focus on genomic research
  • Personalized medicine approaches
  • Integration of immunotherapy with traditional treatments
  • Liquid biopsy and ctDNA monitoring

The IMP continues to collaborate with Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston VA Health Care System, and Harvard School of Public Health.[4]

What Is the Future of Mesothelioma Research Under Dr. Bueno?

Dr. Bueno's research agenda points toward several frontiers in mesothelioma treatment:[15]

Near-Term Goals:

  • Validate genomic biomarkers for treatment selection
  • Identify patients who will respond to immunotherapy
  • Develop targeted therapies for specific mutations
  • Optimize combination treatment sequences

Long-Term Vision:

  • Cure some patients with early-stage disease
  • Convert mesothelioma to a chronic, manageable condition
  • Prevent mesothelioma in high-risk individuals
  • Eliminate asbestos-related disease through prevention and treatment
"The genomic research Dr. Bueno is leading will fundamentally change how we treat mesothelioma. When we can look at a patient's tumor and know which treatment will work best for their specific cancer, outcomes will improve dramatically. That's the promise of personalized medicine."
— David Foster, Client Advocate, Danziger & De Llano

Get Help Today

If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatment approaches—including the personalized medicine pioneered by Dr. Bueno at the International Mesothelioma Program—can significantly impact outcomes. You may also be entitled to compensation from the companies responsible for your asbestos exposure.[16]

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 Call (866) 222-9990 or request a free case review online.

See Also

References

  1. ↑ 1.0 1.1 Genetics and Cancer, National Cancer Institute Cite error: Invalid <ref> tag; name "nci_genetics" defined multiple times with different content
  2. ↑ 2.0 2.1 Malignant Mesothelioma Lawyers, Danziger & De Llano
  3. ↑ Bueno R et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407-416. PubMed
  4. ↑ 4.0 4.1 International Mesothelioma Program, Brigham and Women's Hospital
  5. ↑ 5.0 5.1 5.2 Mesothelioma Diagnosis Guide, Danziger & De Llano
  6. ↑ Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PubMed
  7. ↑ Mesothelioma, National Cancer Institute
  8. ↑ Mesothelioma Treatment Centers, Mesothelioma.net
  9. ↑ 9.0 9.1 Mesothelioma Compensation, Danziger & De Llano
  10. ↑ BAP1 Tumor Predisposition Syndrome, National Cancer Institute
  11. ↑ Mesothelioma Treatment, Mesothelioma.net
  12. ↑ Brigham Mesothelioma Trials, ClinicalTrials.gov
  13. ↑ Clinical Trials for Mesothelioma Treatment, Mesothelioma.net
  14. ↑ Top-Rated Mesothelioma Lawyers, Danziger & De Llano
  15. ↑ New Mesothelioma Treatments and Research, Mesothelioma.net
  16. ↑ What's Your Mesothelioma Case Worth?, Danziger & De Llano
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Dr._Raphael_Bueno&oldid=1693"